OpenSAFELY: Risks of COVID-19 hospital admission and death for people with learning disabilities - a cohort study by Williamson, Elizabeth J et al.
 
OpenSAFELY: Risks of COVID-19 hospital admission and death for 
people with learning disabilities - a cohort study. 
 
 
The OpenSAFELY Collaborative, Elizabeth J Williamson1*, Helen I McDonald1*, Krishnan 
Bhaskaran1, Alex J Walker2, Sebastian Bacon2, Simon Davy2, Anna Schultze1, Laurie 
Tomlinson1, Chris Bates3, Mary Ramsay4, Helen J Curtis2, Harriet Forbes1, Kevin Wing1, 
Caroline Minassian1, John Tazare1, Caroline E Morton2, Emily Nightingale1, Amir Mehrkar2, 
Dave Evans2, Peter Inglesby2, Brian MacKenna2, Jonathan Cockburn3, Christopher T 
Rentsch1, Rohini Mathur1, Angel YS Wong1, Rosalind M Eggo1, Will Hulme2, Richard Croker, 
John Parry3, Frank Hester3, Sam Harper3, Ian J Douglas1, Stephen JW  Evans1, Liam 
Smeeth1†, Ben Goldacre2*†, Hannah Kuper1† 
 




1 London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT 
 
2 The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, 
OX26GG 
 
3 TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX 
 





 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 8, 2021. ; https://doi.org/10.1101/2021.03.08.21253112doi: medRxiv preprint 




Objectives: To assess the association between learning disability and risk of hospitalisation 
and mortality from COVID-19 in England among adults and children. 
  
Design: Working on behalf of NHS England, two cohort studies using patient-level data for 
>17 million people from primary care electronic health records were linked with death data 
from the Office for National Statistics and hospitalization data from NHS Secondary Uses 
Service using the OpenSAFELY platform. 
  
Setting: General practices in England which use TPP software. 
  
Participants: Participants were males and females, aged up to 105 years, from two cohorts: 
(1) wave 1, registered with a TPP practice as of 1st March 2020 and followed until 31st 
August, 2020; (2) wave 2 registered 1st September 2020 and followed until 31st December 
2020 (for admissions) or 8th February 2021 (for deaths). The main exposure group was 
people included on a general practice learning disability register (LDR), with a subgroup of 
people classified as having profound or severe learning disability. We also identified patients 
with Down syndrome and cerebral palsy (whether or not on the learning disability register). 
  
Main outcome measures: (i) COVID-19 related death, (ii) COVID-19 related hospitalisation. 
Non-COVID-19 related death was also explored. 
  
Results: In wave 1, of 14,301,415 included individuals aged 16 and over, 90,095 (0.63%) 
were identified as being on the LDR.  30,173 COVID-related hospital admissions, 13,919 
COVID-19 related deaths and 69,803 non-COVID deaths occurred; of which 538 (1.8%), 221 
(1.6%) and 596 (0.85%) were among individuals on the LDR, respectively. In wave 2, 27,611 
COVID-related hospital admissions, 17,933 COVID-19 related deaths and 54,171 non-
COVID deaths occurred; of which 383 (1.4%), 260 (1.4%) and 470 (0.87%) were among 
individuals on the LDR. Wave 1 hazard ratios for individuals on the LDR, adjusted for age, 
sex, ethnicity and geographical location, were 5.3 (95% confidence interval (CI) 4.9, 5.8) for 
COVID-19 related hospital admissions and 8.2 (95% CI: 7.1, 9.4) for COVID-19 related 
death. Wave 2 produced similar estimates. Associations were stronger among those classed 
as severe-profound and among those in residential care. Down syndrome and cerebral palsy 
were associated with increased hazard of both events in both waves; Down syndrome to a 
much greater extent. Hazards of non-COVID-19 related death followed similar patterns with 
weaker associations. 
 
Conclusions: People with learning disabilities have markedly increased risks of 
hospitalisation and mortality from COVID-19. This raised risk is over and above that seen for 
non-COVID causes of death. Ensuring prompt access to Covid-19 testing and health care 
and consideration of prioritisation for COVID-19 vaccination and other targeted preventive 
measures are warranted.  
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Background 
Identification of high-risk groups for severe outcomes from COVID-19 is critically important in 
risk stratification, including informing vaccine prioritisation and other targeted preventive 
measures. People with learning disability, who total more than one million people in England 
alone or 2% of the adult population, may be one such vulnerable group1. As of February 
2021, the Learning from Death Reviews (LeDeR) programme reported that 1405 people with 
a learning disability had died from COVID-19 in England since February 20202. The true 
number is likely to be far higher due to gaps in registration of learning disability. Emerging 
evidence from the first wave of the COVID-19 epidemic showed that people with learning 
disability were at higher risk from mortality3–7 compared to others in the population. For 
instance, the Oxford RCGP Research and Surveillance Centre (RSC) sentinel network 
reported an odds ratio of 1.96 (95% confidence interval (CI) 1.22 to 3.18) for mortality during 
the first wave of infection in the UK, among people with learning disability compared to those 
without.4 People with Down syndrome may be at particularly high risk; an analysis of primary 
care data from 8 million adults reported a hazard ratio of 10.4 (95% CI 7.1 to 15.2) for 
COVID death associated with Down syndrome.8 However, existing studies on the 
association of learning disability with COVID-19 severe outcomes do not include the second 
wave of the pandemic, and frequently adjusted for variables which might be on the causal 
pathway, such as deprivation and comorbidities, complicating interpretation of the results4. 
There is also lack of clarity on the elevated risk of COVID-19 deaths among individuals with 
milder learning disability, and this needs exploration.9 
  
The higher risks of premature death among people with learning disability in England is well-
known,1,10 and triggered the establishment of GP Learning Disability registers to allow for 
better provision of their healthcare. There are a number of mechanisms by which their risk of 
COVID-19 mortality may also be greater. People with learning disability have a higher 
prevalence of COVID-19 mortality risk factors, including obesity, diabetes, epilepsy and 
poverty.11–13 Medical conditions underlying the learning disability may confer additional risk; 
for instance, people with Down syndrome are more vulnerable to immune dysregulation, 
congenital heart disease and respiratory conditions14. Many people with learning disability in 
England live in residential care or receive community based social care, and therefore have 
frequent contact with carers and other care recipients and face challenges in physical 
distancing. Difficulties understanding protective measures needed, compounded by lack of 
accessible information, further increases their vulnerability to infection. Healthcare access 
and quality, including prevention and treatment, is frequently worse for people with learning 
disability, and leads to avoidable deaths.10  Treatment failures10, including do not resuscitate 
orders15, may increase their risk of death once infected. 
 
Until February 24, 2021, the national recommendations for prioritisation of COVID-19 
vaccination in England included all adults with cerebral palsy, severe or profound learning 
disability, Down syndrome, and the whole resident population in care settings where a high 
proportion of residents would be eligible for vaccination (for example due to learning 
disability).16,17 Consequently, not everyone on the Learning Disability registers was eligible 
for COVID-19 vaccination, in particular people with mild to moderate learning disability from 
causes other than Down syndrome or cerebral palsy who are not living in residential care. 
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This work was undertaken rapidly in response to an urgent need to inform policy-making on 
vaccination prioritisation in the UK and elsewhere. 
 
The aim of this study is to use linked electronic health records within the OpenSAFELY 
platform to rapidly describe the risk of COVID-19 related hospitalisation and mortality among 
children and adults in England with learning disability compared to the general population. A 
subsidiary aim is to separate the risk by types of learning disability (severe-profound; 
cerebral palsy, Down syndrome, learning disability register), including people with learning 
disability not originally included in the first 6 priority groups of the Phase 1 vaccination 
priority list in the UK. 
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Methods 
Study design  
Two population-based observational cohort studies of patients in England were performed 
using data within the OpenSAFELY platform.  
Data  
We used data from primary care linked to secondary care and mortality records in England. 
Records were linked to the NHS England inpatient activity data sets from Secondary Uses 
Service (SUS) data extracts including data from inpatient activity data sets for ascertaining 
COVID-related hospitalisations18; and Office for National Statistics (ONS) death data for 
ascertaining COVID-19 related deaths. The dataset analysed within OpenSAFELY is based 
on 24 million people currently registered with GP surgeries using TPP SystmOne software, 
approximately 40% of the population in England. All data is pseudonymized and includes 
coded diagnoses (using Read version 3, CTV3 codes), medications and physiological 
parameters. No free text data are included.  
Study population 
The first cohort comprised patients (males and females, aged up to 105 years) registered as 
of 1st March 2020 in a general practice which employs the TPP system and followed until 
31st August, 2020. Patients with missing age or a recorded age over 105 years, missing 
gender, or missing postcode (from which much of the household and geographic information 
is calculated) were excluded. The second cohort were similarly defined, but included patients 
registered as of 1st September 2020 in a general practice which employs the TPP system 
and followed until 31st December 2020 (admissions) or 8th February 2021 (deaths). 
Membership of the two cohorts may differ slightly due to patients leaving and joining TPP 
practices and to patients dying prior to the second cohort. These two time periods 
correspond to the two main “waves” of COVID-19 infection experienced in England during 
2020.19 In particular, the 1st September 2020 had the lowest number of COVID-19 related 
deaths since the start of the pandemic.20  
 
Exposures 
All codelists used to define exposure groups are provided online, with links given in the 
Supplementary Materials. The main exposure group was individuals on the learning disability 
register. This register contains a subset of individuals with learning disability; it is not a 
comprehensive list. However, the register provides a simple and practical means of 
identifying people for vaccine prioritisation or implementation of other public health 
measures. A subset of the codes used to define the learning disability register classified the 
learning disability as severe or profound, and were used to class a subset of individuals as 
having severe or profound learning disability.  
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Due to the absence of a comprehensive indicator of residential care, individuals living in a 
household containing at least five individuals identified as being on the learning disability 
register were classed as being in residential care. Households were identified based on GP 
registered addresses as of 1st February 2020, standardised and corrected using publicly 
available house sale data to remove registrations which are likely not current. We use the 
term “residential care” throughout, although we note that this includes a range of settings 
(care homes, educational settings, sheltered accommodation, etc.) and there is likely to be 
misclassification.  
Individuals with Down syndrome and cerebral palsy were identified based on GP codes 
(details in Supplementary Materials).  
Outcomes 
The outcomes for this study are (i) COVID-19 related death (defined as a COVID-19 ICD-10 
code of U07.1 or U07.2 anywhere on the death certificate - ascertained from ONS death 
certificate data)) and (ii) COVID-19 related hospitalisation (defined as admissions with any 
ICD-10 admission diagnosis (not restricted to primary diagnosis) of U07.1 or U07.2 - 
ascertained from SUS data). Individuals who experienced a COVID-19 related 
hospitalisation and then a death contributed to both outcomes. An additional outcome of 
non-COVID-19 related death was also considered (ascertained from ONS death certificate 
data, excluding deaths classed as COVID-19 related).  
Covariates 
Covariates included demographics (age, sex, ethnicity and geographical area), which could 
act as potential confounders, and deprivation (index of multiple deprivation) as a potential 
confounder and/or mediator. To consider mediation by physical comorbidities that are also 
indications for vaccination we included body mass index > 40 kg/m2, chronic cardiac 
disease, atrial fibrillation, deep vein thrombosis/pulmonary embolism, diabetes (further 
grouped by level of control, as measured by the latest HbA1c measurement), chronic liver 
disease, stroke, transient ischaemic attack, dementia, asthma requiring use of oral 
corticosteroids, other chronic respiratory disease, reduced kidney function, dialysis, organ 
transplant, asplenia, other conditions leading to immunosuppression, and haematological 
cancer. We also included non-haematological cancer diagnosed in the last year, rheumatoid 
arthritis/lupus/psoriasis, and inflammatory bowel disease as common indications for 
immunosuppressing medication. These aim to map to the existing physical indications for 
vaccination among 16-64 year olds in England; however data on epilepsy was not available 
for this analysis. To exclude individuals already prioritised for vaccination we additionally 
ascertained other neurological conditions and serious mental illness. These measures were 
obtained from medical records (details in Supplementary Materials).  
 
Statistical methods 
Analysis was undertaken separately for adults 16 years and over and children under 16. The 
three analysis steps below were repeated for the following exposures: being on the learning 
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disability register (all, then divided into severe-profound versus mild-moderate and 
residential care versus non-residential care), Down syndrome and cerebral palsy. 
The two cohorts, for each wave, were analysed separately. Analysis used Cox proportional 
hazards model for (i) COVID-19 related mortality and (ii) COVID-19 related hospital 
admission, stratified by local geographical area, as measured by the Sustainability and 
Transformation Partnership, to account for differing patterns of infection over time in different 
regions, with days in study as the timescale. Follow-up was censored at competing events 
(non-COVID death for mortality analyses and any death for hospital admission analyses) to 
target the cause-specific hazard. Models adjusted for confounders (age, sex, ethnicity), 
additionally for deprivation, residential care status and physical comorbidities (described 
above), and then adjusted for all of these factors simultaneously. Exposure interactions with 
broad age strata (16-<65, 65-<75, 75+) were explored.  
Similar Cox models were fitted for COVID-19 related hospital admission, after excluding 
individuals who were already prioritised for vaccination due to age or comorbidities, as part 
of the first 6 priority groups of Phase I in the UK. These were individuals 65 years and over 
and individuals with codes for physical conditions indicating priority for vaccination described 
above, other neurological conditions, severe mental illness, Down syndrome, cerebral palsy, 
and severe-profound learning disability. These Cox models adjusted for the confounders, 
then separately for deprivation and residential care status.  
 
Finally, Cox models for non-COVID-19 related death were fitted, adjusting for the same 
variables as previous models.  
 
For children under 16 years, these analyses were undertaken separately, omitting analyses 
looking at COVID-19 related death and full adjustment for comorbidities due to much smaller 
numbers of outcomes.  
Missing data 
A complete case approach was taken to missing ethnicity data (~25% of records). Previous 
analyses in these data suggest the assumption required for complete case analysis - that 
missingness is unrelated to outcome given covariates - are approximately satisfied here12. 
Individuals with missing BMI were assumed to be non-obese. Patients with no serum creatinine 
measurement were included in the “no evidence of poor kidney function”. Patients with 
diabetes but no Hba1c measurement were included in a separate “diabetes, no Hba1c” 
category. 
Software and Reproducibility 
The pre-specified study protocol is archived with version control 
(https://github.com/opensafely/Published-
Protocols/blob/master/Learning_Disability_Covid_Protocol_2021_10_02.pdf) 
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Patient and Public Involvement 
We have developed a publicly available website https://opensafely.org/ through which we 
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Results 
Table 1 shows the baseline characteristics of individuals aged 16 and over included in the 
analysis and Table 2 shows characteristics of those under 16 years old (characteristics in 
wave 2 were very similar).  
 
Among 14,301,415 included individuals aged 16 or over, 90,095 (0.63%) were identified as 
being on the learning disability register (Table 1). Of these, 16,115 (18%) were identified as 
having severe-profound learning disability, and 8,027 (9%) as being in residential care. 
8,022 individuals were identified as having Down syndrome, of whom 7124 (89%) were on 
the learning disability register. 18,264 individuals were identified as having cerebral palsy, of 
whom 6,913 (38%) were on the learning disability register. Those on the learning disability 
register were more likely to be male, younger and living in more deprived areas. 
Comorbidities were fairly similar across groups, with more diabetes, obesity, other 
neurological disease, and diagnoses of serious mental illness among those on the learning 
disability register.  
 
Among 2,624,353 included individuals under 16 years (Table 2), 9,114 (0.35%) were 
identified as being on the learning disability register. Of the 2,635 individuals identified as 
having Down syndrome, only 907 (34%) were identified as being on the learning disability 
register. Of the 4,619 individuals identified as having cerebral palsy, 500 (11%) were 
identified as being on the learning disability register.  
 
COVID-19 related hospital admissions and deaths 
Among individuals 16 years and older during wave 1 (1 March 2020 - 31 August 2020; 183 
days), 30,173 COVID-related hospital admissions occurred, 538 (1.8%) among individuals 
on the learning disability register; 13,919 COVID-19 related deaths occured, 221 (1.6%) 
among individuals on the learning disability register (Table 3). 69,803 non-COVID deaths 
occurred, 596 (0.85%) among individuals on the learning disability register. 
 
In wave 2 (1 September 2020 - 31 December 2020 (admissions) or 8 February 2021 (death); 
121 and 160 days, respectively), 27,611 COVID-related hospital admissions occurred, 383 
(1.4%) among individuals on the learning disability register; 17,933 COVID-19 related deaths 
occured, 260 (1.4%) among individuals on the learning disability register. 54,171 non-COVID 
deaths occurred, 470 (0.87%) among individuals on the learning disability register. 
 
Figure 1 shows cumulative COVID-19 related mortality and hospital admissions during the 
study period, accounting for sex, age and ethnicity for individuals on the learning disability 
register and those not. Both graphs show a clear increase in events among those on the 
learning disability register, with a flattening off apparent during the period between waves of 
infection.  
 
Among individuals under 16 years of age, 281 COVID-19 related hospital admissions 
occurred in wave 1 and 292 in wave 2. These numbers cannot be split by learning disability 
status due to stringent redaction rules applied to protect patient privacy. 
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Hazard ratios for COVID-19 hospital admission and death 
Adjusted for age, sex, ethnicity and geographical location, the estimated hazard ratio for 
COVID-19 related hospital admission in wave 1 was 5.3 (95% confidence interval (CI) 4.9, 
5.8) for individuals on the learning disability register (Table 3). For COVID-19 related death, 
the hazard ratio was 8.2 (95% CI: 7.1, 9.4). Wave 2 produced similar estimates (HR for 
COVID-19 related hospital admission 3.6 (95% CI 3.3, 4.0), HR for COVID-19 related death 
7.4 (95% CI 6.5, 8.4)). These associations were stronger among those classed as severe-
profound and among those in residential care. Down syndrome was associated with greatly 
increased hazard of both events in both waves, (wave 1 HR for COVID-19 related hospital 
admission 10.6 (95% CI 8.5, 13.2), wave 1 HR for COVID-19 related death 36.0 (95% CI 
26.4, 49.0; similar numbers for wave 2). Cerebral palsy was associated with higher hazards 
to a lesser extent (wave 1 HR for COVID-19 related hospital admission 4.9 (95% CI 3.8, 
6.3), wave 1 HR for COVID-19 related death 5.9 (95% CI 4.1, 8.3; similar numbers for wave 
2). 
 
Further adjustment for deprivation, residential care and physical comorbidities only slightly 
attenuated these associations (Supplementary tables). The confounder-adjusted hazard 
ratio for wave 1 COVID-19 related hospital admission for being on the learning disability 
register, HR 5.3 (95% CI 4.9, 5.8), reduced to 3.9 (95% CI 3.6, 4.3) after full adjustment. In 
Down syndrome, however, adjustment for both residential care and comorbidities greatly 
attenuated hazard ratios (for example, the wave 1 hazard ratio for COVID-19 related hospital 
admission reduced from 10.6 (95% CI 8.5, 13.2) to 6.3 (95% CI 4.9, 8.2) after adjustment for 
residential care and 7.2 (95% CI 5.8, 9.0) after adjustment for physical comorbidities and 
4.64 (95% CI 3.6, 6.0) after adjusted for all. 
 
Hazard ratios for COVID-19 hospital admission among those under 16 
Among individuals under 16 years old, being on the learning disability register was 
associated with increased hazard of COVID-19 related hospital admissions (wave 1 HR 5.1 
(95% CI 1.9, 14.0), wave 2 HR 8.8 (95% CI 4.9, 15.8), Supplementary Tables).  
  
Effect modification by age 
In wave 1, an interaction was observed between being on the learning disability register and 
age, on the hazard of COVID-19 related death, with those 16-<65 having a hazard ratio 12.3 
(95% CI 10.0, 15.1), 65-<75 HR 10.1 (8.3, 13.3) and 75+ HR 4.2 (95% CI 3.2, 5.5), with 
similar estimates seen for wave 2. A similar interaction was not observed for COVID-19 
related hospital admission in either wave.  
Hazard ratios among individuals not prioritised for vaccination 
After excluding people 65 years and older and those with comorbidities listed above, the 
estimated hazard ratio of COVID-19 related hospital admission was 6.7 (95% CI 1.6, 28.2) 
after adjustment for age, sex, ethnicity and geographical location, with little change after 
adjustment for deprivation or residential care status. Too few events were observed to 
analyse finer groupings or wave 2 events.  
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Hazard ratios for non-COVID-19 death 
Adjusted for age, sex, ethnicity and geographical location, the estimated hazard ratio for 
non-COVID-19 related death was 3.7 (95% CI 3.4, 4.0) in wave 1 and 3.9 (3.6, 4.) in wave 2. 
Associations were stronger among those classed as having severe-profound learning 
disability. Associations were slightly stronger among those classed as being in residential 
care. Down syndrome was associated with a greatly increased hazard of non-COVID-19 
related death (wave 1 HR 12.3 (95% CI 10.0, 15.2; similar numbers for wave 2). Cerebral 
palsy was associated with higher hazards to a lesser extent (wave 1 HR for COVID-19 
related death 3.2 (95% CI 2.6, 4.0; similar numbers for wave 2). 
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Discussion 
Our data show a higher risk of hospitalisation and deaths for all the groups with learning 
disability relative to comparators. Generally, the pattern of hazard ratios is consistent for 
waves 1 and 2, and hospitalisations and deaths. Hazard ratios appear slightly lower for wave 
2 than wave 1 for both hospitalisations and deaths. Higher risks were observed among those 
with severe-profound learning disability compared to mild-moderate, which was not 
explained by measured physical comorbidities or residential care status. However, the 
absolute number of deaths was higher among people with mild-moderate learning disability. 
For Down Syndrome and cerebral palsy, we observed higher risk among those on the 
learning disability register. Higher risk remains among those on the learning disability 
register who do not have Down syndrome or cerebral palsy, compared to the general 
population. This is not explained by measured physical comorbidities or residential care 
status. After excluding people who were prioritised for vaccination among groups 1-6 of 
Phase I in England due to reasons of age or comorbidity, those on the learning disability 
register had a remaining substantial increased risk of COVID-19 related hospital admission. 
Higher risks of non-COVID-19 related deaths were also observed in people with learning 
disabilities, though associations were much less strong than for COVID-19 death; this is in 
contrast with most other risk factors which appear to have a similar magnitude of association 
with both COVID-19 related and non-COVID-19 related death21.   
Findings in context 
Our findings are consistent with the existing literature. The Oxford RCGP Research and 
Surveillance Centre sentinel network, including 4.4 million people nationally representative 
from England, reported two-fold higher mortality among people with learning disability (OR 
1.96, 95% CI 1.22, 3.18, p<0.01) after extensive adjustment4. Public Health England used 
different sources of data and estimated that, up to June 2020, people with learning disability 
had approximately 6.3 times the mortality rate as the general population22. Overall, COVID-
19 was responsible for at least half of deaths among people with learning disability during 
this period. Data from Scotland also showed that adults with intellectual disabilities had 
higher rates of COVID-19 infection, severe infection and mortality5. Elevated risks remained 
after adjusting for age, sex and deprivation (Standardised severe infection ratio: 2.59, 95% 
CI 1.80, 3.39; Standardised mortality ratio 3.20 95% CI 2.1, 4.25). Higher mortality rate 
among people with learning disability has also been demonstrated in Wales6, New York 
State7, and the USA more broadly3. Not only are death rates higher for people with learning 
disability, but deaths occur at younger ages3,8,9,22. Indeed, the particularly elevated mortality 
rates among younger people with learning disability noted in our study have also been 
reported in the USA3. 
  
The particularly high risk for people with Down Syndrome was demonstrated for the first 
wave by Clift and colleagues using the QResearch population level primary care database8. 
In their cohort of 8 million adults in England from January to June 2020, the age- and sex-
adjusted hazard ratio for COVID-19 death for adults with versus without Down syndrome 
was 24.94 (95% CI 17.08, 36.44), which reduced to 10.39 (95% CI 7.08, 15.23) after 
extensive adjustment (deprivation, BMI, cardiovascular, pulmonary and other disease, 
residential status, ethnicity). Data for cerebral palsy is more limited, but the QResearch 
analyses showed a higher mortality rate for this group (2.66, 95% CI 1.62, 4.36). Clift and 
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colleagues obtained a fully adjusted hazard ratio of 1.27 (95% CI 1.16, 1.40) for COVID-19 
death in those with learning disabilities other than Down syndrome, in contrast to our higher 
estimates. This discrepancy is likely due to differences in adjustment. We chose not to adjust 
for many comorbidities, viewing many of these as consequences of the learning disability 
thus part of the causal pathway. In our analyses, children with learning disability had a 
higher risk of hospital admission for COVID-19, notwithstanding the extremely small 
numbers. Similarly, existing studies also indicate that children with learning disability are 
more vulnerable to requiring hospitalization and critical care due to COVID-19 outcomes23–26. 
Evidence on mortality remains lacking for children. 
 
The hazard rates for COVID-19 outcomes in our study attenuated after adjustment for 
deprivation. Residential status also partially explained the higher risks of severe COVID-19 
outcomes in people with learning disability. However, residential care for people with 
learning disability may not raise risk as much as in other care settings, perhaps because 
there are generally fewer beds22 in these facilities. An important driver appears to be 
comorbidities, reflecting the higher prevalence of these COVID-19 risk factors among people 
with learning disability11,13. However, large excess mortality rates remained after extensive 
adjustment, as is also apparent in previous studies8. This pattern implies that other drivers 
may be relevant, including inherent clinical vulnerabilities for people with certain conditions 
and concerns about healthcare quality, as also indicated by the higher case fatality rates 
among people with learning disability (Scotland: 30% versus 24%5; New York: 15,0% versus 
7.9%7; USA 18-74 year olds: 4.5% versus 2.7%3). 
    
Strengths and weaknesses 
Key strengths and weaknesses of the OpenSafely platform have been outlined previously12. 
An important strength for the current analyses is that the study is large, including records of 
approximately 40% of the English population, allowing disaggregation by learning disability 
grouping. We had comprehensive data on participants from medical records, allowing us to 
adjust analyses successively to explore mechanisms for the association of learning disability 
and adverse COVID-19 outcomes. Furthermore, we were able to assess excess risks in both 
waves 1 and 2 of the COVID-19 epidemic, in terms of both hospitalization and mortality 
outcomes. We considered children as well as adults. 
  
There are also important limitations. It is not possible to identify everyone with a learning 
disability from medical records alone, which may have under-estimated hazard ratios. For 
instance, the most recent data, from 2015, suggests that 23% of people with learning 
disability are included on the registers1. Our hospitalisation data included only completed 
hospital admissions, thus will have under-ascertained this outcome towards the end of wave 
2. Data was not available on epilepsy, which is both a COVID-19 risk factor and more 
common among people with learning disability11,13. We also had an incomplete measure of 
residential care. There was missing data, in particular for ethnicity, although we do not 
anticipate that this had a meaningful impact on the results. We did not have data on quality 
of treatment and so were not able to explore all our hypothesised pathways between 
learning disability and adverse COVID-19 outcomes. Furthermore, these analyses focussed 
only on severe COVID-19 outcomes, and did not explore impacts on physical and mental 
health of people with learning disability which are likely to occur as a result of lockdown and 
other restrictions23 and require mitigation. We focused on the general population, so our 
analyses explore the combination of infection and severe outcomes once infected, thus we 
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are unable to disentangle associations with those two steps in the process. However, 
focusing on the infected only would induce biases due to unrepresentative testing.   
 
Policy implications and interpretation 
In February, 2021, the Joint Committee on Vaccination and Immunisation updated its 
guidance27 to include everyone on the Learning disability registers, as well as people with 
Down Syndrome, cerebral palsy or in residential care, as priority groups to receive the 
vaccine. This change was informed by a prior version of this analysis, demonstrating the 
increased risk in the remaining group. The current Learning Disability registers are 
incomplete1, however, and updating them will facilitate this and future prioritization 
exercises. Many other countries (e.g. Germany28, USA29) currently focus on prioritizing 
people living in care homes and those with Down Syndrome for vaccination, and should 
consider broadening this category to include other people with learning disability. Raised 
risks seen among those under 16 years suggest that vaccination in this age group warrants 
further consideration. Besides vaccination, efforts should continue to protect people with 
learning disability from COVID-19 adverse outcomes, including through consideration of 
non-pharmacological interventions such as shielding, and ensuring adequate support to 




The ONS data shows that people with disabilities in general are at higher risk of COVID-19 
mortality30, but this has not yet been explored through the clinical databases, in part because 
of the complexity of generating codelists for these broad range of conditions. The example of 
the Learning Disability register data has, however, highlighted the importance of public 
health surveillance and the need to develop indicators for disability. More research is 
warranted on the excess COVID-19 risks among people with Down Syndrome. Cerebral 
palsy includes people with a broad range of conditions and severity, and a deeper 
exploration or COVID-19 risk for this group is warranted. 
  
Conclusion 
People with learning disabilities have markedly increased risks of hospitalisation and death 
from COVID-19. Ensuring prompt access to Covid-19 testing and health care and 
consideration of prioritisation for COVID-19 vaccination and other targeted preventive 
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Table 1. Baseline characteristics of individuals 16 years and older 
Characteristic 
On the learning 
disability register 
N (%) 
Not on the 
 learning disability register 
N (%) 
Total  90,095 (100) 14,211,320 (100) 
Agegroupa 
   16-<45 52,120 (58) 6,355,662 (45) 
   45-<65 29,100 (32) 4,629,591 (33) 
   65-<70 3,881 (4) 888,739 (6) 
   70-<75 2,705 (3) 894,454 (6) 
   75-<80 1,370 (2) 622,363 (4) 
   80+ 919 (1) 820,511 (6) 
   Female 36,702 (41) 7,350,940 (52) 
   Male 53,393 (59) 6,860,380 (48) 
Ethnicity 
   White 81,104 (90) 12,039,335 (85) 
   Black 1,715 (2) 402,038 (3) 
   South Asian 5,445 (6) 1,174,749 (8) 
   Mixed 1,125 (1) 206,754 (1) 
   Other 706 (1) 388,444 (3) 
Region 
   East 18,379 (20) 3,283,255 (23) 
   London 3,631 (4) 1,166,640 (8) 
   Midlands 21,529 (24) 3,157,325 (22) 
   North East, Yorkshire and the 
Humber 19,593 (22) 2,712,531 (19) 
   North West 10,193 (11) 1,243,992 (9) 
   South East 5,229 (6) 855,933 (6) 
   South West 11,541 (13) 1,791,644 (13) 
Index of multiple deprivation 
   1 (Least deprived) 9,677 (11) 2,801,547 (20) 
   2 13,799 (15) 2,893,839 (20) 
   3 17,042 (19) 2,861,727 (20) 
   4 21,566 (24) 2,877,708 (20) 
   5 (Most deprived) 28,011 (31) 2,776,499 (20) 
Learning disability and related 
Mild-moderate learning disability 73,980 (82) - 
Severe-profound learning disability 16,115 (18) - 
Not in residential care 82,068 (91) 14,209,944 (>99) 
Residential care 8,027 (9) 1,376 (<1) 
No Down's syndrome 82,971 (92) 14,210,422 (>99) 
Down's syndrome 7,124 (8) 898 (<1) 
No Cerebral Palsy 83,182 (92) 14,199,969 (>99) 
Cerebral Palsy 6,913 (8) 11,351 (<1) 
Comorbidities 
BMI>40 (Obese III) 5,911 (7) 382,436 (3) 
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Asthma (with OCS use) 878 (1) 129,409 (1) 
Cystic fibrosis 35 (<1) 3,733 (0) 
Respiratory disease 3521 (4) 574,188 (4) 
Chronic cardiac disease 5,642 (6) 915,275 (6) 
Atrial fibrillation 2,313 (3) 507,129 (4) 
Deep vein thrombosis/ 
Pulmonary embolism 2,075 (2) 291,614 (2) 
Diabetes 
   With HbA1c < 58 mmol mol−1 6,794 (8) 852,854 (6) 
   With HbA1c ≥ 58 mmol mol−1 3,425 (4) 400,577 (3) 
   With no recent HbA1c measure 1,324 (1) 159,392 (1) 
Liver disease 461 (1) 85,489 (1) 
Stroke 1,965 (2) 286,782 (2) 
Transient Ischaemic Attack 933 (1) 216,932 (2) 
Dementia 1,895 (2) 168,852 (1) 
Other neurological disease 8,816 (10) 129,587 (1) 
Reduced kidney function 
   Stage 3a/3b, eGFR 30-60 2,827 (3) 714,068 (5) 
   Stage 4/5, eGFR<30 521 (1) 68,475 (<1) 
Dysplenia 142 (<1) 23,042 (<1) 
Organ transplant 191 (<1) 12,969 (<1) 
Conditions leading to 
immunosuppression 483 (1) 40,744 (<1) 
Haematological malignancy 
   Diagnosed last year 25 (<1) 7,130 (<1) 
   Diagnosed 2-5 years ago 79 (<1) 21,655 (<1) 
   Diagnosed >5 years ago 284 (<1) 49,514 (<1) 
Cancer (non-haematological) in last 
year 195 (<1) 62,859 (<1) 
RA/SLE/psoriasis 4,272 (5) 710,001 (5) 
Inflammatory bowel disease 866 (1) 178,662 (1) 
Serious mental illness 8,015 (9) 168,213 (1) 
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Table 2. Baseline characteristics of individuals under 16 years old 
Characteristic 
On the learning 
disability register 
N (%) 
Not on the 
 learning disability register 
N (%) 
Total 9,114 (100) 2,615,239 (100) 
   Female 2,965 (33) 1,275,295 (49) 
   Male 6,149 (67) 1,339,944 (51) 
Ethnicity 
   White 6,971 (76) 2,070,441 (79) 
   Black 369 (4) 96,159 (4) 
   South Asian 1,256 (14) 277,942 (11) 
   Mixed 299 (3) 99,477 (4) 
   Other 219 (2) 71,220 (3) 
Region 
   East 1,743 (19) 618,596 (24) 
   London 552 (6) 167,325 (6) 
   Midlands 2,188 (24) 608,128 (23) 
   North East, Yorkshire and the 
Humber 2,050 (22) 493,649 (19) 
   North West 966 (11) 224,103 (9) 
   South East 566 (6) 169,577 (6) 
   South West 1,049 (12) 333,861 (13) 
Index of multiple deprivation 
   1 (Least deprived) 1,215 (13) 485,858 (19) 
   2 1,383 (15) 471,778 (18) 
   3 1,584 (17) 483,503 (18) 
   4 2,069 (23) 533,144 (20) 
   5 (Most deprived) 2,863 (31) 640,956 (25) 
Learning disability and related 
Mild-moderate learning disability 7,740 (85) - 
Severe-profound learning disability 1,374 (15) - 
Not in residential care 9,054 (99) 2,615,192 (>99) 
Residential care 60 (1) 47 (>1) 
No Down's syndrome 8,207 (90) 2,613,511 (>99) 
Down's syndrome 907 (10) 1,728 (<1) 
No Cerebral Palsy 8,614 (95) 2,611,120 (>99) 
Cerebral Palsy 500 (5) 4,119 (<1) 
Comorbidities   
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 Table 3. Estimated hazard ratios for COVID-19 outcomes among adults 16 years and over, adjusted for potential confounders (age, sex, 
ethnicity, geographical region) 
 
Wave 1 (1 Mar 2020 – 31 Aug 2020) 
 
Wave 2 (1 Sept 2020 – Nov 2020 (admissions) or Jan 2021 
(death)) 
 
COVID-19 hospital  
admission COVID-19 related death 
COVID-19 hospital  





HR (95% CI) 
 Events HR (95% CI) Events HR (95% CI) Events HR (95% CI) 
         
LDR         
   No 29,635 
 
13,698  27,228  17,673  
   Yes 538 5.33 (4.88, 5.83) 221 8.18 (7.12, 9.39) 383 3.64 (3.28, 4.03) 260 7.39 (6.52, 8.38) 
by severity:         
   Mild-moderate 391 4.76 (4.32, 5.25) 158 7.1 (6.08, 8.3) 281 3.27 (2.91, 3.67) 179 6.2 (5.37, 7.17) 
   Severe-profound 147 7.8 (6.47, 9.4) 63 13.21 (9.99, 17.48) 102 5.27 (4.31, 6.44) 81 12.81 (10.25, 16) 
by residential care status:         
   Not in residential care 438 4.89 (4.46, 5.37) 182 7.82 (6.77, 9.02) 318 3.36 (2.99, 3.76) 211 6.92 (6.04, 7.94) 
   In residential care 100 8.77 (6.8, 11.3) 39 10.42 (6.88, 15.78) 65 6.14 (4.58, 8.22) 49 10.41 (7.51, 14.43) 
Down's syndrome         
   No 30,098 
 
13,878  27,558  17,868  
   Yes 75 10.56 (8.45, 13.2) 41 35.96 (26.38, 49.02) 53 7.22 (5.52, 9.46) 65 42.91 (33.54, 54.9) 
Cerebral Palsy         
   No 30,076 
 
13,889  27,536  17,902  
   Yes 97 4.93 (3.84, 6.34) 30 5.86 (4.14, 8.3) 75 3.7 (2.93, 4.69) 31 4.54 (3.19, 6.47) 
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Figure 1: Cumulative (a) COVID-19 mortality and (b) COVID-19 hospital admission or 
mortality for individuals on the learning disability register and not with 95% CI, standardised 
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